Atelerix launches STORganoid ambient-temperature preservation solution for organoids and spheroids
Atelerix, a Newcastle-based biotech company specialising in hydrogel encapsulation technology, has announced the launch of STORganoid™, an ambient-temperature preservation solution designed for the storage and shipment of organoids and spheroids. The product aims to address a persistent logistical barrier to the broader use of complex three-dimensional (3D) cell models in research and drug development.
The challenge of preserving complex 3D cell models
New Approach Methodologies (NAMs) are attracting growing regulatory support, but reliable transport of human-relevant 3D cell models remains problematic. Organoids and spheroids are highly sensitive to temperature fluctuations, and conventional cryo-preservation and hypothermic approaches can compromise their structural and functional integrity. This has effectively confined their routine use to specialist laboratories, limiting global research access.
Hydrogel encapsulation at the core
STORganoid leverages Atelerix’s proprietary hydrogel technology to stabilise cell membrane integrity at ambient temperature, removing the requirement for cold-chain logistics. The system
stores organoids and spheroids in an assay-ready format, eliminating time-consuming culture procedures following transport. The product is designed to support transfer of complex models between geographically distributed sites without loss of viability or reproducibility.
Steve Swioklo, CSO and Co-founder of Atelerix, commented: “STORganoid addresses one of the key barriers to broader adoption of these highly predictive cell-based models by freeing them from
the constraints of specialised laboratory environments and lengthy culture protocols. We are proud to be contributing to the harmonisation and accessibility of new approach methodologies (NAMs), helping to bring cutting-edge science closer to real-world application.”
Applications and market positioning
STORganoid expands Atelerix’s portfolio of fresh biosample storage products and is positioned to support applications across drug discovery, disease modelling, and personalised medicine.
The company states it represents a scalable solution aligned with the growing organoid and cell therapy markets, facilitating wider distribution and new research partnerships globally.
For more information, visit: https://www.atelerix.co.uk/stororganoid
Digital issue: Please click here for more information
